VIVES is a multi-sector fund that invests in projects with a positive societal impact
ViroVet is a pioneering company developing innovative technologies to combat viral diseases in livestock. They focus on antiviral drugs for complex respiratory illnesses and novel vaccines to protect...
Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent cardiovascular risks.
Cardio...
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
Chris Buyse, co-founder and Managing Partner of Fund+:
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Willem de Vos, Prof. at University of Wageningen; Patrice Cani, Prof. at UCLouvain; Jean-Christophe Malrieu, CEO A-Mansia:
"As founders and CEO of A-mansia BioTech we experienced essential support...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is